Amarin Corporation publishes REDUCE-IT findings in JACC, demonstrating VASCEPA/VAZKEPA benefits in high-risk cardiovascular disease patients with varying Lipoprotein(a)
Amarin Corporation presents REDUCE-IT findings showing VASCEPA/VAZKEPA (icosapent ethyl) benefits in high-risk cardiovascular disease patient subgroups with baseline high/low Lipoprotein(a) [Lp(a)] levels and irrespective of baseline LDL-C level. Results are published in Journal of the American College of Cardiology (JACC). This new data supports the clinical utility of VASCEPA/VAZKEPA in reducing cardiovascular events in at-risk patients.
April 06, 2024
5 Articles